Osimertinib is the only third-generation EGFR tyrosine kinase inhibitors clinically approved for first-line treatment of advanced NSCLC patients harboring EGFR mutations. However, drug resistance ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...